The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia

• Sponsor: Northwestern University (Other)
• Overall Status: Withdrawn
• CT.gov ID: NCT03048461
• Collaborator: (none)
• Enrollment: 0
• Arms: 2
• Anticipated Duration (Months): 18

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effect of autologous platelet-rich plasma (PRP) in the treatment of androgenetic alopecia.

This is a randomized clinical trial to evaluate the effect of autologous platelet rich plasma in subjects with moderate androgenetic alopecia. Approximately 30 subjects will be randomized into the study. The study is designed as an 18-month study consisting of 2 phases. This study was a pilot study designed to determine feasibility of this procedure.

Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.

Condition or Disease	Intervention/Treatment	Phase
Androgenetic Alopecia	Device: Platelet Rich Plasma Prep System; Drug: Placebo	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 0 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Effect of Autologous Platelet-rich Plasma in Subjects With Androgenetic Alopecia.
• Anticipated Study Start Date: Jun 1, 2019
• Anticipated Primary Completion Date: Dec 1, 2020
• Anticipated Study Completion Date: Dec 1, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Platelet Rich Plasma Participants will receive intradermal injections autologous PRP to an area (100cm2) of alopecia on the scalp.Two treatments will be performed 3 months apart	Device: Platelet Rich Plasma Prep System; intradermal injections of platelet rich plasma to an area of alopecia
Placebo Comparator: Placebo (sterile saline) Participants will receive intradermal injections of sterile normal saline to an area (100cm2) of alopecia on the scalp. Two treatments will be performed 3 months apart	Device: Platelet Rich Plasma Prep System; intradermal injections of platelet rich plasma to an area of alopecia; Drug: Placebo; intradermal injections to an area of alopecia

Outcome Measures

Primary Outcome Measures

1. Clinical change of androgenetic alopecia, as determined by scoring photographs [Baseline to 6 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 55 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Males or females ≥ 18 years old and ≤55 years old

2. Subjects are in good health as judged by the investigator.

3. Diagnosed with by a dermatologist with moderate androgenetic alopecia.

4. Subject is seeking treatment for androgenetic alopecia.

5. Subject has never previously used finasteride or minoxidil or has consistently used finasteride or minoxidil for at least 1 year.

6. Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator.

Exclusion Criteria:

1. Other than androgenetic alopecia, evidence of another skin condition affecting the treatment area that would interfere with clinical assessments.

2. Subjects who are unwilling to avoid initiating treatment with minoxidil or finasteride for the duration of the study; or in subjects who have been treated with minoxidil or finasteride for at least 1 year, unwilling to avoid changes in the dosing regimen of these medications for the duration of the study.

3. Willing to refrain from washing hair or using hair product 24 hours before and after treatment visits

4. History of a clinically significant hematologic disorder as determined by the investigator.

5. Subjects currently receiving anticoagulant or anti-platelet therapy.

6. Subjects on daily Aspirin therapy for cardiovascular disease.

7. Subjects with chronic NSAID use, unable to wean off.

8. Subject is known to be HIV positive.

9. History of recurrent facial or labial herpes simplex infection

10. History of hypertrophic scars or keloids

11. Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, etc.

12. Subjects who have any requirement for the use of local or systemic steroids or other immunosuppressive agent

13. Pregnant or breast feeding

14. Uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.

15. Subjects who are unable to understand the protocol or give informed consent.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Northwestern University

Investigators

• Principal Investigator: Murad Alam, MD, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Murad Alam, MD, Northwestern University
• ClinicalTrials.gov Identifier: NCT03048461
• Other Study ID Numbers: MA04222016
• First Posted: Feb 9, 2017
• Last Update Posted: Dec 23, 2021
• Last Verified: Dec 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Additional relevant MeSH terms: Alopecia; Alopecia Areata

Study Results

No Results Posted as of Dec 23, 2021